Apogee Therapeutics
OrganizationHeard in 2 episodes across 1 show since Jun 2026
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of immunological and inflammatory disorders. The company's pipeline targets conditions with high unmet needs, including atopic dermatitis, chronic obstructive pulmonary disease (COPD), and asthma.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 2 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What experts have said about Apogee Therapeutics
2 statements · 2 positive
Apogee’s psoriasis compound could rival Sanofi’s Dupixent.
“it could be a rival to France's Sanofi and its blockbuster Dupixit”
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX DeclineListen at 1:25
AbbVie is nearing an approximately $11 billion acquisition of Apogee.
“AbbVie is closing in on a nearly $11 billion deal to buy Apogee.”
Open the episode · Arcosa and Apogee Rise; Getty JumpsListen at 1:51
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Apogee Therapeutics, newest first
